Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Open Access
- 8 June 2026
- journal article
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1532-1534
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Acute promyelocytic leukemia: long-term outcomes from the HARMONY projectBlood, 2025
- Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trialAnnals of Hematology, 2024
- Acute myeloid leukemiaJAAPA, 2024
- Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapyBlood Advances, 2021
- Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trialLeukemia, 2019
- Poisson Approximation-Based Score Test for Detecting Association of Rare VariantsAnnals of Human Genetics, 2016
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaNew England Journal of Medicine, 2013
- Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood, 1988
- Acute Promyelocytic Leukemia: Results of Treatment by DaunorubicinBlood, 1973
- Acute Promyelocytc LeukemiaActa Medica Scandinavica, 1957